RE
Lunai Bioworks Inc.
RENB · NASDAQ
$1.42 +0.00% (+$0.00)
Valuation
-
N/A P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
-
N/A ROIC N/A
Asset turnover N/A
ROE N/A
Debt
-
N/A Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Stability
82 /100
Stable Beta 0.53x
Rev. volatility N/A
Profitable years N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RENB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David H. Weinstein
Employees
25
Headquarters
Los Angeles